ArticleEpilepsia open2025
Real world testing and cost-effectiveness analysis of subcutaneous EEG (REAL-ASE): Protocol for a prospective multicentre interventional trial.
Article in Epilepsia open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Monitoring Antiseizure Medication Change Using Ultra Long-Term Electroencephalogram: A Multicenter Study.Annals of neurology · 2026Article
- Review
- Ultra long-term EEG monitoring for developmental and epileptic encephalopathies: protocol for a prospective study using subscalp EEG.Clinical neurophysiology practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveEpilepsy is a common condition associated with significant morbidity, mortality, and costs. Poor documentation of seizures is a major challenge in epilepsy care. Objective seizure counting with mobile devices may mitigate this challenge and improve patient management. The aim of this study is to investigate whether ultra long-term subcutaneous EEG improves seizure documentation and disease monitoring in people with drug-resistant epilepsy.
methodsReal World Testing and Cost-effectiveness Analysis of Subcutaneous EEG (REAL-ASE) is a UK-based multi-centre prospective interventional study with an expected duration of 7 months. Thirty-three adult participants will be implanted with 24/7 EEG SubQ and collect 2-channel EEG data for 6 months. Data will be reviewed and annotated by experts, and a summary sent to the treating clinician weekly. The treating clinician will communicate information from this annotation report to participants monthly. Changes in management can be made at the treating clinician's discretion. REAL-ASE was approved by the Bromley Research Ethics Committee in July 2023 (reference number 23/LO/0419).
resultsWe anticipate that subcutaneous EEG may improve seizure documentation and be a well-accepted addition to epilepsy care by clinicians and patients. We believe it will be associated with better quality of life and will be a cost-effective solution. SIGNIFICANCE: If our study demonstrates improved seizure documentation with subcutaneous EEG, this may contribute to patient safety, improved quality of life, and a reduction in healthcare costs. PLAIN LANGUAGE SUMMARY: We present a clinical trial protocol for a prospective cohort study of 33 people with epilepsy across the UK. The study aims to assess whether an EEG implant placed under the skin: (1) is more accurate than patient-reported seizure diary, (2) is feasible and acceptable to patients and clinicians, (3) reduces the impact of epilepsy, and (4) is beneficial to the National Health Service (NHS).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.